Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to -$962000.0.

  • Tonix Pharmaceuticals Holding's Cash from Investing Activities fell 1058888.89% to -$962000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 million, marking a year-over-year decrease of 54051.09%. This contributed to the annual value of -$120000.0 for FY2024, which is 9958.72% up from last year.
  • Tonix Pharmaceuticals Holding's Cash from Investing Activities amounted to -$962000.0 in Q3 2025, which was down 1058888.89% from -$2.5 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Cash from Investing Activities ranged from a high of -$3000.0 in Q4 2024 and a low of -$24.0 million during Q2 2023
  • Moreover, its 3-year median value for Cash from Investing Activities was -$626000.0 (2023), whereas its average is -$3.3 million.
  • Per our database at Business Quant, Tonix Pharmaceuticals Holding's Cash from Investing Activities surged by 9930.39% in 2024 and then tumbled by 1058888.89% in 2025.
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Cash from Investing Activities stood at -$431000.0 in 2023, then skyrocketed by 99.3% to -$3000.0 in 2024, then crashed by 31966.67% to -$962000.0 in 2025.
  • Its Cash from Investing Activities stands at -$962000.0 for Q3 2025, versus -$2.5 million for Q2 2025 and -$6000.0 for Q1 2025.